A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study

Huang, Yizhou; Chen, Lizhi; Zhong, Tang; Yu, Min; Yu, Wanli; Yang, Gangyi; Zhang, Lili

doi:10.3389/fendo.2021.774244

Cited by 8 publications

(8 citation statements)

References 39 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 40% of patients with ER-positive breast cancer have defects in the DNA repair mechanism, which is an important factor contributing to endocrine resistance in breast cancer. A study revealed that compared to patients with low ERCC1 expression, (30,31). Multivariate regression analysis revealed that vascular tumor thrombus is an independent prognostic factor for patients with breast cancer.…”

Section: Discussionmentioning

confidence: 99%

“…This increases the risk of lymph node and distant metastasis in patients with breast cancer. Vascular tumor thrombus indicates poor prognosis in patients with breast cancer and can predict distant metastasis and local recurrence of tumors ( 30 , 31 ). Multivariate regression analysis revealed that vascular tumor thrombus is an independent prognostic factor for patients with breast cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer

Liao²,

Ma³

2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo investigate the relationship between Excision repair cross-complementation 1 (ERCC1) expression, clinicopathological features, and breast cancer prognosis in patients treated with trastuzumab. Further, we aim to explore the immune status of ERCC1 in breast cancer.MethodsThe data were retrieved from publicly available databases like the Cancer Genome Atlas, Therapeutically Applicable Research to Generate Effective Treatments, and the Genotype-Tissue Expression. The data was used to perform differential expression analyses between tumor and normal tissues in pan-cancers, immune-related analysis, homologous recombination deficiency (HRD), tumor mutation burden, and microsatellite instability. A total of 210 patients with HER2 over-expressing breast cancer from the Fourth Hospital of Hebei Medical University between January 2013 to December 2015 were enrolled in the study. Ten adjacent normal tissues were used to study the expression pattern of ERCC1 in normal tissues. Immunohistochemistry was performed to study ERCC1 expression and immune cell infiltration in different status of ERCC1 expression. Further, the correlation between ERCC1 expression, immune cell infiltration clinicopathological features, and the prognosis of patients with breast cancer was analyzed.ResultsThe immune analysis revealed a significant correlation between CD8+ T cell, CD4+ T cell, T helper cell, macrophages, mast cells, and ERCC1 expression. Spearman analysis show that ERCC1 expression is related to macrophages and T cells. A close correlation was observed between increased ERCC1 expression and high tumor immune dysfunction and exclusion (TIDE) score as well as HRD. The results revealed a significant correlation among ERCC1, chemotherapy and estrogen receptor (ER; P < 0.05) expression. Univariate survival analysis revealed a significant correlation (P < 0.05) between that ERCC1 and ER expression, blood vessel invasion, and disease-free survival (DFS). ERCC1 and ER expression, tumor size, blood vessel invasion, pathological type, and lymph node metastases significantly correlated (P < 0.05) with overall survival in patients. Multivariate regression analysis revealed that ERCC1 expression and chemotherapy were independent factors that influence DFS. ERCC1 expression and vascular tumor thrombus were independent influencing factors that influence OS.ConclusionA correlation was observed between high ERCC1 expression and poor patient prognosis. High ERCC1 expression also influences the efficacy of immunotherapy and chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer

Liao²,

Ma³

2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Another TCGA analysis that assessed core genes associated with breast cancer status revealed SLAMF6/CD352 as one of eight core genes. However, SLAMF6 had only a weak association with survival (P=0.042) and no significant association with tumor (T), node (N), and metastases (M) (TNM) status and was not further assessed ( 20 ).…”

Section: Slamf Receptors In Solid Tumorsmentioning

confidence: 99%

Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors

Gunes,

Rosen,

Shachar

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Recently, cancer immunotherapy has revolutionized cancer treatment. Various forms of immunotherapy have a manageable safety profile and result in prolongation of overall survival in patients with solid tumors, but only in a proportion of patients. Various factors in the tumor microenvironment play critical roles and may be responsible for this lack of therapeutic response. Signaling lymphocytic activation molecule family (SLAMF) members are increasingly being studied as factors impacting the tumor immune microenvironment. SLAMF members consist of nine receptors mainly expressed in immune cells. However, SLAMF receptors have also been detected in cancer cells, and they may be involved in a spectrum of anti-tumor immune responses. Here, we review the current knowledge of the expression of SLAMF receptors in solid tumors and tumor-infiltrating immune cells and their association with patient outcomes. Furthermore, we discuss the therapeutic potential of targeting SLAMF receptors to improve outcomes of cancer therapy in solid tumors. We believe the research on SLAMF receptor-targeted strategies may enhance anti-cancer immunity in patients with solid tumors and improve clinical outcomes.

show abstract

“…Approximately 1 decade ago, immune infiltration in the TME was observed as a prognostic factor that should not be ignored [9]. According to recent research, tumor-infiltrating immune cells (TICs) and stromal components play an important role in the development of breast cancer [10,11], colorectal cancer [12], and cutaneous melanoma [13].…”

Section: Introductionmentioning

confidence: 99%

GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer

Lin¹,

Zhu²,

Mao³

et al. 2023

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

Background: Immune infiltration of the tumor microenvironment offers unlimited possibilities for therapeutic strategies in cervical cancer, where GRAP2 is an adaptor protein engaged in diverse signal activations. However, uncertainty exists regarding GRAP2's prognostic significance and its relationship to immune infiltration. Methods: The data on cervical cancer cases were downloaded from The Cancer Genome Atlas (TCGA) database. The ESTIMATE computational technique was utilized to calculate the amount of immunological and stromal components, which helped us to identify the differential expression genes (DEGs). Among them, GRAP2 was considered to be related to overall survival based on a protein-protein interaction network and a univariate Cox regression analysis. Thus, based on the Gene Expression Omnibus (GEO) and TCGA databases, we evaluated GRAP2's influence on clinical prognosis. Furthermore, GRAP2 expression was analyzed by Gene Set Enrichment Analysis (GSEA). Finally, we used CIBERSORTx analysis to assess the proportion of tumor-infiltrating immune cells (TICs) and the connection between GRAP2 and the tumor immune microenvironment. Results: ES-TIMATEScore was associated with cervical cancer patient's prognosis. There are 791 DEGs and 11 potential key genes were identified including GRAP2. In survival analyses with clinical information, We found that the GRAP2 high expression group exhibited a significantly longer overall survival (OS) than the low expression group and that the gene expression gradually declined as the Federation of International of Gynecologists and Obstetricians (FIGO) stage and M classification increased. GRAP2 was strongly linked with immunity and metabolism, according to GSEA. Finally, we discovered that 11 different TIC types and GRAP2 expressions were linked. Conclusions: GRAP2 may be a novel immune-related prognosis biomarker in cervical cancer.

show abstract

A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study

Cited by 8 publications

References 39 publications

ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer

ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer

Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors

GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer

Contact Info

Product

Resources

About